Publications by authors named "Peter H Norman"
Article Synopsis
- The study investigates whether a new ventilatory strategy called VESPA can reduce atelectasis, a condition that complicates peripheral bronchoscopy and affects imaging accuracy in patients under general anesthesia.
- In a randomized controlled trial with 76 patients, those utilizing the VESPA strategy had a significantly lower occurrence of atelectasis (28.9%) compared to the standard ventilation group (84.2%).
- Despite the effectiveness of VESPA in minimizing atelectasis, the study found no differences in complications between the two ventilation methods.
Preclinical studies have demonstrated that opioid receptor agonists increase the rate of non-small cell lung cancer (NSCLC) growth and metastasis. Following institutional review board approval, we retrieved data on 901 patients who underwent surgery for NSCLC at MD Anderson Cancer Center. Comprehensive demographics, intraoperative data, and recurrence-free survival (RFS) and overall survival (OS) at 3 and 5 years were obtained.
View Article and Find Full Text PDFObjective: The objective of this study was to evaluate whether the use of a video double-lumen tube reduced the need for fiberoptic bronchoscopy for (1) verification of initial tube placement and for (2) reverification of correct placement after repositioning for thoracotomy.
Design: A single-center retrospective study.
Setting: Thoracic surgery in a medical university hospital.
Background: Aprotinin has been used to decrease blood loss with complicated cardiac surgery but has not been investigated in extrapleural pneumonectomy, an operation that does not use cardiopulmonary bypass. In this prospective, randomized, placebo-controlled, double-blind trial, the authors investigated whether aprotinin decreased blood loss in patients who underwent this operation.
Methods: After appropriate statistical design and institutional review board approval, eligible patients who were scheduled for extrapleural pneumonectomy were randomized to receive either aprotinin or placebo during the operation.
Study Objective: To describe the adverse events associated with the intraoperative injection of isosulfan blue in a large group of patients having a wide range of surgical procedures, and to identify risk factors for these events.
Design: Retrospective chart review.
Setting: University-affiliated institution specializing in malignancies
Patients: 1835 patients representing a total of 1852 surgical procedures.